Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.1.1.34 (
lipoprotein lipase
)
7,025
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Bacterial endotoxin/lipopolysaccharide (LPS)-induced cachexia is characterized by weight loss,
anorexia
, and a disturbance in lipid metabolism, namely, hypertriacylglycerolemia. The aim of this study in rats with acute endotoxicity induced by an injection of LPS was to investigate whether bezafibrate, a ligand for peroxisome proliferator-activated receptor alpha and a
lipoprotein lipase
(
LPL
) activator, improved cachectic conditions, including impaired lipid metabolism. Short-term administration of LPS in the rats resulted in impairment of triacylglycerol clearance in plasma after the intake of fresh cream. In addition, LPS increased whole-body energy expenditure, reduced fasting body weight and caused
anorexia
in the rats. Bezafibrate treatment resulted in significant improvements in LPS-induced dyslipidemia and
anorexia
, but had no effect on energy expenditure, respiratory quotient, or fasting body weight in the endotoxic rats. Administration of LPS was also associated with a decrease in the level of messenger RNA (mRNA) expression for
LPL
in white adipose tissue and skeletal muscle and an increase in the mRNA levels for uncoupling protein 3 in skeletal muscle. Bezafibrate treatment reversed the decline in
LPL
mRNA levels in white adipose tissue but not in the skeletal muscle tissue of the rats. The enhanced uncoupling protein 3 mRNA level in the endotoxic rats was not affected by bezafibrate treatment. Plasma concentration of leptin was increased by short-term LPS treatment. Bezafibrate decreased the level of plasma leptin significantly without affecting the level of leptin mRNA expression. These results suggest that bezafibrate may be an effective drug not only for impaired triacylglycerol metabolism, but also for
anorexia
in cachectic states induced by bacterial infections.
...
PMID:Bezafibrate improves bacterial lipopolysaccharide-induced dyslipidemia and anorexia in rats. 1737 10
Hypothalamic lipid sensing is important for the maintenance of energy balance. Angiopoietin-like protein 3 (Angptl3) critically regulates the clearance of circulating lipids by inhibiting
lipoprotein lipase
(
LPL
). The current study demonstrated that Angptl3 is highly expressed in the neurons of the mediobasal hypothalamus, an important area in brain lipid sensing. Suppression of hypothalamic Angptl3 increased food intake but reduced energy expenditure and fat oxidation, thereby promoting weight gain. Consistently, intracerebroventricular (ICV) administration of Angptl3 caused the opposite metabolic changes, supporting an important role for hypothalamic Angptl3 in the control of energy balance. Notably, ICV Angptl3 significantly stimulated hypothalamic
LPL
activity. Moreover, coadministration of the
LPL
inhibitor apolipoprotein C3 antagonized the effects of Angptl3 on energy metabolism, indicating that
LPL
activation is critical for the central metabolic actions of Angptl3. Increased
LPL
activity is expected to promote lipid uptake by hypothalamic neurons, leading to enhanced brain lipid sensing. Indeed, ICV injection of Angptl3 increased long-chain fatty acid (LCFA) and LCFA-CoA levels in the hypothalamus. Furthermore, inhibitors of hypothalamic lipid-sensing pathways prevented Angptl3-induced
anorexia
and weight loss. These findings identify Angptl3 as a novel regulator of the hypothalamic lipid-sensing pathway.
...
PMID:Regulation of energy balance by the hypothalamic lipoprotein lipase regulator Angptl3. 2533 13
<< Previous
1
2